Who
David Canner
Director
Company insider
Files Form 4 as: Director, Inhibikase Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 21 Oct 2024
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,176 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,640 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,585 at $0.00 | filing |
| 21 Oct 2024filed 23 Oct 2024 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.